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I  Introduction and rationale
In recent years an increasing number of cannabis 
products, including herbal cannabis and cannabis oils, 
have been offered for open sale in Europe. These products 
claim to contain only low levels of tetrahydrocannabinol 
(THC), the chemical responsible for most of the 
psychoactive effects of cannabis, and therefore might not 
be controlled under drug laws in some countries. This 
development has given rise to concerns at the policy level 
with regard to both the legal status of these products and 
their potential to cause harm. A specific challenge, and one 
that is faced by both policymakers and those wishing to 
supply low-THC products, lies in establishing the legal 
status of low-THC products and which regulatory 
frameworks apply to their sale. In particular, there are 
uncertainties associated with those low-THC products that 
take forms similar to illicit cannabis products, such as 
smoking mixtures, oils and edibles. These products are the 
primary focus of this report.
With a view to mapping this phenomenon and beginning to 
address knowledge gaps, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) initiated an 
exploratory trendspotter study in the autumn of 2018.
It is important to note that the analysis provided here is 
intended as a purely descriptive exercise that describes, as 
far as it is possible, the current situation in an area that is 
complex, politically and commercially sensitive and highly 
dynamic. While this is helpful for informing discussion in 
this area, the reader should note that nothing in this report 
is intended as a recommendation or constitutes any form 
of legal or other opinion on how low-THC products should 
be regulated. Furthermore, the EMCDDA perspective is 
that of a drug monitoring agency. As low-THC products 
have appeared in areas that fall under the competencies of 
other EU agencies and bodies, while we have done our 
best to describe the situation as far as we understand it, 
this report does not necessarily represent the views of any 
other parties with responsibilities in this area. Finally, we 
have summarised various legal frameworks that may be 
relevant to low-THC products in this report. However, these 
descriptions are provided for the purposes of this report 
only and are not intended to be used or have meaning 
beyond this.
The study applied the trendspotter methodology, which 
involves the triangulation of data from a range of sources, 
in this case including a literature review, a web survey and 
an expert meeting (see box ‘The trendspotter 
methodology’, on page 5). In addition, information 
received during discussions with the EMCDDA’s network 
of legal and policy correspondents was included.
This publication brings together the study’s findings with 
regard to the overall aim of providing an initial overview of 
the situation in Europe with respect to the open sale of 
low-THC products. The specific objectives were to identify 
and further explore the types of product available and the 
range of sales outlets, user profiles, associated harms and 
responses taken in different EU countries.
A number of significant developments have taken place in 
selected European countries since the original data were 
collected and, where possible, updates have been 
included. Nevertheless, it is important to acknowledge that 
this is a rapidly evolving area and one with relatively limited 
information currently available. Thus, the findings 
presented here will necessarily be incomplete, and they 
need to be viewed as an introduction to the situation and 
pertinent issues, as well as providing a platform for further 
research and monitoring.
The following sections of this report summarise the study’s 
findings and its analyses. Where results are based on the 
literature, references are cited; otherwise, the findings are 
based on EMCDDA and national monitoring and the 
qualitative sources mentioned above.
I What are low-THC cannabis products?
There is some debate over what is included within the term 
low-THC cannabis products. The definition of low-THC 
cannabis products used in this publication is ‘products 
being or containing cannabis herb, resin, extracts or oils 
that claim or appear to have a very low percentage of THC 
and which would be unlikely to cause intoxication’. They 
may be marketed for their low THC levels or for their high 
cannabidiol (CBD) levels. The definition excludes licensed 
medicines and products that use cannabis plant fibre only, 
such as textiles. It should be noted that some products 
containing extracts from the cannabis plant or its seeds 
have also appeared as cosmetics or foodstuffs; in this 
report we concentrate on those smoked or ingested 
products that are more likely to pose risks to public health. 
The classification of an individual product as a food, 
cosmetic or herbal smoking product is defined by EU and 
national provisions and is discussed in the section ‘The 
regulatory context for low-THC products’ (see page 10).
Cannabis flowers and extracts contain a wide variety of 
chemically related substances collectively known as 
cannabinoids. The percentage of each cannabinoid can 
vary greatly by plant variety and by growing technique. The 
two most extensively studied cannabinoids are THC and 
CBD. THC produces effects such as feeling ‘high’, 
relaxation and altered perception – the effects that people 
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who use cannabis recreationally usually seek from the 
drug – while CBD does not result in the same intoxicating 
effects as THC.
This means that CBD is generally not considered to have 
the sort of psychoactive profile associated with drugs used 
recreationally or for their intoxicating properties. However, 
it should be noted that the action of CBD on the brain is a 
complicated topic and is not discussed in detail here.
Moreover, some commentators have noted an association 
between the use of CBD and some health benefits. 
However, the evidence for the effectiveness of CBD for 
most conditions that have been studied is limited, and 
many of the health benefits claimed remain topics 
requiring further research (EMCDDA, 2018). Again this is 
not an issue reviewed in any detail in this publication.
I The situation in Europe regarding   low-THC products
I Types of low-THC products
A wide variety of low-THC cannabis products is now 
available in Europe. These include those that mirror 
established illicit cannabis products, such as herb, resin 
and oil, and other types of smoking products, such as 
e-liquids and crystals. Cannabis-infused edible products 
are also on sale, both as ready-to-eat products and 
beverages and as ingredients such as flour and pasta. 
Other cannabis products, such as balms, creams and 
pastes, are also available.
The study found that low-THC cannabis products were 
being offered for sale in the majority of EU countries 
(Table 1). As the low-THC phenomenon has expanded to 
more countries, so has the range and variety of types of 
low-THC cannabis products available across sales outlets, 
with oil and herbal products being the most commonly 
identified forms reported here. Resin products appear to 
This exploratory study used the EMCDDA’s trendspotter 
methodology, which draws on a range of different 
investigative approaches and uses data from multiple 
sources (EMCDDA, 2018). The investigation was divided 
into two main phases, as illustrated below. The first phase 
included a survey of and meetings with the EMCDDA 
legal and policy correspondents’ network, input from 
the EMCDDA reference group on drug supply indicators 
and a non-systematic review of routine sources and of 
scientific and grey literature (including desk research 
into sales websites). In addition, with a view to improving 
the geographical coverage, an online survey was sent to 
the EMCDDA Reitox network of national focal points (16 
respondents). The second investigative phase centred on 
an expert meeting, held in Lisbon in November 2018. The 
event was attended by 12 experts from seven countries, 
who presented information on the situation in their 
country, participated in facilitated working groups and 
contributed to an in-depth analysis of the topic, providing 
insights from a range of perspectives, including industry, 
shopkeepers, law enforcement agencies, medicines 
regulation authorities and drug research organisations.
Analysis was based on triangulation of all the information 
sources, with a view to providing as complete and verified 
a picture as possible.
The trendspotter methodology
Literature 
review
Data 
review
Online  
surveys
Analyses and
integration Expert
presentations
Facilitated
groups
Final 
analysis
Phase 1 Phase 2
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be less common. Table 1 provides a snapshot of the 
situation, using limited sources, as at February 2019. The 
data presented are likely to be incomplete, and may not 
reflect the current situation in terms of the types of 
product available in individual countries. Nevertheless, the 
table illustrates both the widespread availability of these 
products across Europe and their diversity.
I The sale of low-THC products in Europe
Some of the earliest developments in the low-THC market 
in Europe are reported to have taken place in Switzerland. 
In 2011 Switzerland increased the limit defining how a 
cannabis plant is classified under the Narcotics Control 
Act from 0.3 % to 1 % THC, in order to take into account 
measurement uncertainty and biological variability in 
industrial hemp production. While some entrepreneurs 
started to market low-THC cannabis products based on 
this limit, there was no significant change in the market 
immediately following the introduction of the higher limit. 
However, the number of cannabis products on offer 
containing CBD has expanded since mid-2016 (Zobel et 
al., 2019), when one company marketed a large amount of 
‘low-THC’ cannabis product, regulated as a ‘tobacco 
substitute product’ with associated health warnings and 
taxation levels. Once the information began to disseminate 
that products containing less than 1 % THC were not 
subject to cannabis legal controls in Switzerland, the 
marketing of these low-THC cannabis products increased.
Following the expansion in the sale of low-THC cannabis 
products in Switzerland, similar situations arose in 
TABLE 1
Types of low-THC cannabis-based products advertised for sale in the EU and Norway, February 2019
Country Herb Resin Oil E-liquids Edible products Crystals
Austria X X X X X X
Belgium X X X X X –
Bulgaria – – X – – –
Croatia X – X X X X
Cyprus X – – X – –
Czechia X X X – X –
Denmark – – X – – –
Estonia – – – – – –
Finland – – – – – –
France X X X X – X
Germany X X – X – X
Greece X X X X X X
Hungary – – X – X –
Ireland X X X X – X
Italy X X X – X X
Latvia – – – – – –
Lithuania X – X X – –
Luxembourg X – X – X –
Malta – – X X – –
Netherlands – X X X X –
Poland X – X X – –
Portugal – – X – –
Romania X – X X – –
Slovakia – – – – X –
Slovenia X X X X X –
Spain X X X – – –
Sweden X – X X X –
Norway – – – – – –
United Kingdom X – X X X –
Note: The reported advertising of a product in a country at the time of the survey is indicated by a cross (X).
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neighbouring countries. These new products were 
observed in Austria from March 2017 and Italy from May 
2017, before spreading to Germany, Belgium and France 
by early 2018.
Informants in this study highlighted the fact that there may 
have been a widespread assumption that, in accordance 
with Regulation (EU) No 1307/2013, on granting payments 
to (hemp) farmers, any product containing less than 0.2 % 
THC was not restricted by law and could be advertised and 
sold to the public. The Regulation was not intended to 
imply that.
I Types of retailers
In the European context, the low-THC market is 
characterised by a wide variety of retailers. While 
cannabis-themed products can now be found in everyday 
retail outlets, such as health food chain stores, chemists 
and cafes, there are also dedicated shops selling low-THC 
cannabis products. Some of these specialised shops focus 
on health and well-being, while others are more closely 
associated with the recreational cannabis market, having 
more in common with tobacconists, ‘vape shops’ or Dutch 
cannabis ‘coffeeshops’.
In this report, for the sake of simplicity, these two types of 
shop will be referred to as either ‘health/lifestyle shops’ or 
‘tobacco/coffeeshops’. However, in reality, the boundaries 
between the two types can be fluid and there may be 
overlap in the types of product sold and the method of 
selling. Either type of shop may sometimes offer literature 
about the health benefits of the products or accessories, 
such as lighters, pipes and grinders, or sometimes 
cannabis seeds and cultivation equipment such as plant 
pots and lighting.
The specific nature of the shops and sales mechanisms, 
whether they are bricks and mortar or primarily online, 
varies from country to country. In some countries, such as 
Austria, Greece and Luxembourg, there are vending 
machines selling low-THC cannabis products. Some shops 
and brands offer to deliver their products throughout the 
EU, others to a limited list of countries and some only 
within their base country. Following the introduction of 
Regulation (EU) 2018/302 in December 2018, online 
sellers are no longer permitted to block customers from 
other EU Member States, except in the case of countries 
with laws that prohibit the sale of these products. 
Nevertheless, some suppliers state that it is the 
responsibility of the buyer to check the laws and 
regulations of the destination country.
Herbal products appear to be more commonly sold by 
tobacco/coffeeshops, while health/lifestyle shops tend to 
stock CBD products such as creams and balms. Overall, it 
seems that there is not always a clear distinction in the 
type of products sold in different shops. What tends to 
differ is the marketing strategy used, with the same 
product being promoted or advertised differently 
depending on the focus of the retailer and the intended 
customer base.
In some countries, certain shops, both health/lifestyle 
shops and tobacco/coffeeshops, may act as wholesalers 
supplying low-THC products to other shops. For example, it 
was reported that in Belgium several new shops were 
offering such business-to-business connections, 
encouraging other shops to sell their stock and keeping a 
percentage of the profit.
I Origin of the products
Information on the source of the supply of low-THC 
cannabis products is not consistently provided by 
suppliers. In this study, the types of information reported 
on the origin of products included the specific location 
(e.g. the country); the manufacturer; whether produced 
domestically or imported; whether grown indoors or 
outdoors; and sometimes claims that they were sourced 
from certified producers. A brief review of retailers 
advertising low-THC products on the internet also found 
claims that their sources are ‘EU-approved hemp varieties’ 
and examples that indicated cultivation in a wide range of 
countries including Austria, Croatia, Czechia, France, 
Germany, Greece, Italy, Montenegro, Morocco, the 
Netherlands, Poland, Spain, Switzerland and Slovenia. 
However, it was also reported that declarations of origin 
may not always be accurate; experts reported cases in 
which import documents on postal packages had been 
mislabelled to hide their true origin.
I Product quality
Reports from the study indicate that there is wide variation 
in product quality and this gives rise to a number of 
concerns. These include whether the product matches 
what is claimed in terms of the actual content, particularly 
with respect to levels of CBD and THC, and whether there 
are contaminants, which may be a particular issue for 
substances that will be ingested but can also apply more 
generally.
Independent product testing was reported by several 
countries, including Austria, Czechia, Finland, Italy, 
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Slovenia and Sweden. In Austria, Italy and Luxembourg, 
analyses of confiscated products were reported to show 
generally low THC but high CBD levels, with Italy reporting 
some samples with levels of CBD in the 50-60 % range. In 
Austria, from a sample of around 200 products, 49 were 
found to be above the legal limit for THC, with several 
showing 0.4-1.1 % THC rather than the 0.3 % permitted 
(Federal Ministry of Social Affairs, Health, Care and 
Consumer Protection, personal communication), putting 
the sellers at risk of prosecution. In Czechia, tests of 29 
CBD oils in 2017-2018 found that one third had 
discrepancies with the amount of CBD stated on the label 
(ICCI, 2018). THC was not mentioned on 60 % of labels, 
although one quarter of the samples may have resulted in 
a driver testing positive after taking the recommended 
dose of oil. Some products sold as ‘high in CBD’ therefore 
contained levels of THC that could potentially have 
resulted in noticeable intoxication if consumed in sufficient 
volumes (see box ‘Challenges in defining appropriate levels 
of THC in legislation’, on page 14). 
Tests of CBD oils also found known carcinogens, including 
polycyclic aromatic hydrocarbons (PAHs) and 
benzopyrene, above the maximum levels set for oils and 
oil-containing food supplements in European Commission 
Regulations (EU) No 835/2011 and (EU) 2015/1933, 
respectively. In two batches tested, the maximum levels 
set for benzo(a)pyrene and the sum of four PAHs were 
exceeded in approximately half of the samples tested. The 
highest levels found were seven times the limit set for 
benzo(a)pyrene and almost 20 times the limit set for the 
sum of four PAHs. One batch of supposedly ‘organic’ 
product contained traces of a pesticide banned 20 years 
ago.
This variability in CBD content and the potential presence 
of significant levels of THC and potentially harmful 
contaminants have also been reported in other studies 
(Pavlovic et al., 2018; Gibbs et al., 2019).
I Marketing of low-THC products
The marketing of low-THC cannabis products, including 
both promotion and advertising, varies between and within 
countries. Many low-THC cannabis products are marketed 
and sold online through dedicated websites. Prices may or 
may not be displayed and the option to make a purchase 
may or may not be provided. For example, in Luxembourg 
there were websites where the products were displayed 
without information on pricing, and the customer was 
directed to a physical location to make a purchase. Social 
media are also used for product promotion and advertising 
but seem to be rarely used as purchase platforms, 
although in some cases purchase is possible through 
direct messaging.
Some retailers tend to focus on providing information on 
the inherent properties of the product, for example the 
variety of cannabis, content, flavour and aroma. Other 
retailers emphasise the product’s lifestyle aspects, for 
example whether it is vegan, gluten free, organic or 
environmentally friendly.
Information on the perceived health benefits of the 
products, primarily CBD-related, may also be provided, 
either directly in relation to the product itself or indirectly by 
providing links to research and scientific papers. For CBD 
products, the typical dosage may be suggested, usually 
expressed in terms of drops or millilitres in a given period.
Health claims appear to be a significant contributor to the 
demand for CBD-related products. Although the evidence 
base in this area remains limited, there are claims that 
CBD improves well-being and helps to eliminate or 
alleviate a variety of health problems, including anxiety, 
insomnia, loss of appetite, digestive problems, migraines 
and breathing problems, and that it can act as an 
antidepressant and painkiller. These claims are often made 
on CBD sales websites or in promotional material. 
Examples also exist of claims that CBD may be used for 
the treatment of psoriasis and other skin problems, 
glaucoma and multiple sclerosis, and that it strengthens 
the immune system. However, health claims for foods 
should be authorised under Regulation (EC) No 
1924/2006 on nutrition and health claims made on foods, 
and no such health claims have been authorised for 
cannabis products. 
It is important in this context to note that CBD does have 
approved medical use for a limited number of medical 
conditions, and the scientific literature was summarised in 
recent EMCDDA reports (EMCDDA, 2018; Hall, 2018). A 
plant-derived CBD oral solution was approved by the US 
Food and Drug Administration in June 2018 (as Epidiolex), 
and by the European Medicines Agency in September 
2019 (as Epidyolex), as an adjunctive therapy for seizures 
associated with Lennox-Gastaut syndrome or Dravet 
syndrome (intractable childhood epilepsy).
In summary, a number of regulatory challenges can be 
identified concerning the marketing and promotion of 
some CBD products. These include inadequate product 
labelling; inconsistent content; potentially poor product 
quality; a lack of acknowledgement of the limitations, or 
overstating, of the evidence concerning the effectiveness 
of CBD products for therapeutic use; and a lack of safety 
information or information on potential harms and possible 
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contraindications. However, it is also important to note 
that, while these issues may give rise to legitimate 
consumer protection and safety concerns, to date, there is 
very little evidence of any reported harms in Europe, either 
in the scientific literature or anecdotally associated with 
these products. At the same time, it should also be noted 
that this is not an area in which robust monitoring currently 
takes place, and rare or long-term problems associated 
with the use of these products may be difficult to detect.
I Product labelling and disclaimers
Some items being marketed as CBD or low-THC products, 
particularly those being sold as health or well-being 
products, include label information on the levels of CBD 
and THC in the product, generally by weight (in milligrams) 
or as a percentage. In the case of THC, this may be 
presented as a percentage that will not be exceeded (e.g. 
less than 0.2 % THC), and in some cases claims may be 
made that the product is certified THC-free or that the 
content is below the level stated. The label may also 
provide some guidance on the dosage, including the 
maximum amounts to use.
Often the products are labelled by the seller as food 
supplements or as room scenting products, and 
sometimes the intended mode of use is given, such as for 
smoking or another form of consumption. However, 
products are not always presented in a consistent way; the 
same or a similar item may be presented in different ways 
in different shops or countries.
In some cases disclaimers suggest how the products 
should not be classified or used. While product disclaimers 
are not common, those identified tended to fall into three 
categories:
   health disclaimers: the product should not be used to 
treat diseases; the sellers state that they are not 
responsible if the product is misused;
  consumption disclaimers: the product is not intended 
for consumption, not recommended for smoking or not 
to be burned because of the risk of cancer; the product 
is for collectible purposes only;
  user-related disclaimers: the product is not for use by 
minors, not recommended for women who are pregnant 
or breastfeeding and not to be used while driving.
The use of product labelling and disclaimers may indicate 
how retailers of low-THC cannabis products are mindful of 
the legal frameworks that may permit or restrict the sale of 
such products. Examples include praising the taste, yet 
stating that the product is not for consumption or selling, 
for example, herbal products with warnings that the 
products are only collectibles.
In addition, differences between countries in the use of 
disclaimers and marketing methods indicate that retailers 
are aware of the country-specific legal frameworks and the 
environment in which they are operating and seek to adapt 
to these.
It is interesting to note that some countries, such as 
Austria, have already responded to the phenomenon and 
classified various products. By classifying low-THC herbal 
cannabis products as ‘herbal smoking products’, it 
becomes necessary to display health warnings and sale to 
minors becomes restricted. To illustrate this, it was 
reported that one product with a picture of a unicorn on 
the label was considered illegal as a smoking product, as it 
might appeal to minors.
I Characteristics and motivations of users of      low-THC products
The information available on consumers and consumption 
of low-THC cannabis products, including the former’s 
characteristics and motivations, is extremely limited. In 
Switzerland, a survey of over 1 500 CBD users was 
conducted by Addiction Switzerland in 2019. The 
respondents were recruited through Facebook and a 
community of interest, with around one third reporting use 
of CBD products on more than 20 days a month, about 
three quarters reporting using cannabis flowers and more 
than half also reporting using illicit cannabis (Zobel et al., 
2019). In this survey, three main motivations for use were 
identified: (1) for well-being (to combat stress or insomnia); 
(2) for health (to treat pain, depression, nausea); and (3) to 
moderate their use of illicit cannabis (to reduce illegal use 
or the effects of THC).
The study also found that people with health-related 
motivations for use had an older age profile than those 
motivated by lifestyle or an interest in experimenting with 
products similar to the established illicit cannabis products. 
Consumers with health motivations were more likely to 
purchase products from health/lifestyle shops and included 
respondents reporting mistrust of big pharmaceutical 
companies and seeking natural products as self-
medications or as food supplements. Finally, respondents 
reporting motivations for use associated with their use of 
illicit cannabis were younger than the other two groups and 
more likely to purchase from tobacco/coffeeshops.
An Austrian market survey, conducted in July 2019, 
explored CBD-containing product awareness and use 
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among a sample of internet users aged 16-69 years 
(sample size 1 009) (1). Of the respondents, 14 % reported 
that they had experience of CBD-containing products, and 
almost a quarter (23 %) said that they had acquaintances 
who had tried such products. Three quarters of these said 
that they had a positive experience with the product, and 8 
out of 10 suggested that they were likely to use CBD again 
in the future. Younger respondents (aged 16-29 years) 
were more likely to report having used CBD: 22 % reported 
that they had used CBD at some time, compared with 13 % 
of 30- to 49-year-olds and 10 % of 50- to 69-year-olds. 
While the survey method may have resulted in a sample 
that over-represents the type of people who might use 
CBD-containing products, it is interesting to note that the 
sample extended across all age groups in the population.
I The regulatory context for low-THC products
The United Nations (UN) drug control conventions provide 
the basis for national drug control laws and state that 
unauthorised sale of ‘cannabis flowers’ and ‘extracts and 
tinctures of cannabis’ should be subject to criminal 
penalties. However, the conventions do not apply to the 
cultivation of cannabis plants for industrial purposes (e.g. 
fibre, seed). There is no explicit mention of CBD in the UN 
conventions, which has resulted in different interpretations 
of whether plant-derived CBD should be considered an 
‘extract of cannabis’ or a substance unlikely to be abused 
and therefore not requiring control. It should also be noted 
that synthetic forms of CBD can be produced that are not 
derived from extracts of cannabis plants.
The EU has many directives and regulations that may be 
applicable to low-THC cannabis products in their different 
forms and components, and which provide standardised 
definitions of different types of products, such as foods, 
food supplements and medicines. Some of these may 
apply automatically and uniformly to all EU Member States; 
others will need to be transposed into national law (see 
box ‘Main EU legislation to be considered in the context of 
regulating low-THC cannabis products’, on page 12).
In addition, the assessment of the legislation applicable to 
individual products is a complex process and carried out on 
a case by case basis. Clarification may be requested from 
the relevant departments of the European Commission.
Criteria have been established within the EU to define 
different categories of cannabis plant varieties, and some 
may be cultivated and supplied for hemp fibre if they have 
low levels of THC. The granting of payments under the 
(1) Web survey conducted for Magu-CBD. 
common agricultural policy is conditional on the use of 
certified seed of specified hemp varieties; only varieties 
with a THC content not exceeding 0.2 % may be used 
(Regulation (EU) No 1307/2013). This limit applied to the 
agricultural production of cannabis varieties may have 
given rise to the belief that any finished product containing 
less than 0.2 % THC is not restricted by law and may be 
legally made available to consumers.
In fact the 0.2 % limit in EU law is intended only as a criterion 
for the granting of EU payments for agriculture; higher 
national limits may be established for other purposes.
The EU plant variety database lists varieties whose seed 
can be marketed throughout the EU, including 
approximately 70 varieties of the species ‘hemp – 
Cannabis sativa’ (European Commission, 2019b). Some 
EU Member States may explicitly exclude all derivatives of 
those varieties from their narcotic schedules. This includes 
all parts of the plant, seeds, extracts and tinctures, as well 
as the resin. Imports of hemp are also subject to certain 
conditions to ensure that the THC limit is respected 
(Regulation (EU) No 1308/2013). It should be stressed, 
however, that this legislative framework was developed for 
the hemp industry. Therefore, it cannot necessarily be 
assumed that it is appropriate to apply it to products 
intended for human consumption.
As there are many health claims around low-THC and 
primarily CBD products, it is also relevant to consider the EU 
legislation regarding medicines in this context. Directive 
2001/83/EC establishes that a medicinal product is one that 
restores, corrects or modifies physiological functions by 
exerting a pharmacological action or is presented as having 
properties intended to treat or prevent disease. In this way 
the directive, which lays down the requirements and 
procedures for marketing authorisation of medicinal 
products for human use, applies to medicinal products 
containing cannabis derivatives, requiring a marketing 
authorisation for any sale. Marketing authorisation is granted 
for a specific product if the safety, quality and efficacy of that 
product to treat a disease is confirmed. Recently, EU-wide 
marketing authorisation has been granted to the medicinal 
product Epidyolex, a plant-derived CBD oral solution, 
indicated for the treatment of seizures associated with 
Lennox-Gastaut syndrome or Dravet syndrome in children 
aged 2 years or older. While health claims appear to be a 
significant contributor to the demand for CBD products on 
open sale, there is, however, currently limited evidence 
available on the effectiveness of CBD products for many 
other conditions for which effectiveness has been claimed.
Furthermore, cannabis-infused edible products have been 
on sale in many EU Member States, whether ready-to-eat 
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products and beverages or ingredients such as flour and 
pasta. Various regulations may be relevant here: 
Regulation (EC) No 178/2002 lays down the general 
principles of and requirements for food law and states that 
the definition of ‘food’ does not include medicinal 
products, cosmetics or narcotic or psychotropic 
substances within the meaning of the 1961 and 1971 UN 
conventions, implying that substances regarded in the 
conventions as narcotic or psychotropic substances 
cannot be classified as foods. A special category exists for 
novel foods, which in simple terms can be defined as foods 
that had not been consumed to a significant degree by 
humans in the EU before 15 May 1997, when this 
regulation first came into force. The EU Novel food 
catalogue serves as orientation on whether a product will 
need an authorisation under the novel food Regulation. It 
is important to note that the catalogue is not formally part 
of EU food legislation, as it serves as only a guidance 
document and has no formal legal meaning.
The catalogue contains the following guidance under the 
heading ‘Cannabis sativa L.’:
In the European Union, the cultivation of Cannabis 
sativa L. varieties is permitted provided they are 
registered in the EU’s ‘Common Catalogue of Varieties 
of Agricultural Plant Species’ and the tetrahydro-
cannabinol (THC) content does not exceed 0.2 % (w/w). 
Some products derived from the Cannabis sativa plant 
or plant parts such as seeds, seed oil, hemp seed flour, 
defatted hemp seed have a history of consumption in 
the EU and therefore, are not novel. Other specific 
national legislation may restrict the placing on the 
market of this product as a food or food ingredient in 
some Member States. Therefore, it is recommended to 
check with the national competent authorities. 
(European Commission, 2019c).
Under the headings ‘Cannabidiol’ and ‘Cannabinoids’, the 
EU Novel food catalogue has a note that reads:
There was a request whether this product requires 
authorisation under the Novel Food Regulation. 
According to the information available to Member 
States’ competent authorities, this product was not 
used as a food or food ingredient before 15 May 1997. 
Therefore, before it may be placed on the market in the 
European Union as a food or food ingredient a safety 
assessment under the Novel Food Regulation is 
required. (European Commission, 2019c).
Food business operators can place a novel food on the EU 
market only after the Commission has processed an 
application for the authorisation of a novel food and has 
adopted an implementing act authorising the placing on 
the market of a novel food.
Currently there appear to be some developments in this 
area of applying for authorisation of novel foods (Norwinski 
et al., 2019). Over 60 applications were made for the 
authorisation of CBD-containing products under 
Regulation (EU) 2015/2283 on novel foods. It is for the 
European Commission to verify whether individual 
applications fall within the scope of the Regulation. This 
includes a verification of whether the specific product falls 
within the definition of ‘food’ laid down in the General Food 
Law Regulation ((EC) No 178/2002). Doubts have been 
raised on whether CBD can be considered a ‘food’ as the 
General Food Law excludes from this definition 
substances considered as narcotic or psychotropic 
substances within the meaning of the UN drug 
conventions (2). 
Furthermore, the cosmetics regulation (Regulation (EC) No 
1223/2009) requires notification of new products on the 
EU market to the EU Cosmetic product notification portal, 
and several cosmetic products containing CBD can be 
found there.
In accordance with the relevant EU provisions (such as the 
definition of a medicinal product under Directive 2001/83/
EC and the definition of a cosmetic product in Regulation 
(EC) No 1223/2009), the Member States national 
competent authorities will determine the classification for 
any individual product, on a case-by-case basis, and in this 
way it would be possible for a ‘borderline’ product to be 
classified as a medicine in one country and a food in a 
second country. The introduction to the European 
Commission’s Cosmetic ingredients (CosIng) database 
highlights this point:
If, due to such ingredients, a product restores, corrects, 
or modifies physiological functions by exerting a 
pharmacological, immunological or metabolic action, 
the product shall be qualified as a medicinal product. 
However, products that, while having an effect on the 
human body, do not significantly affect the metabolism 
and thus do not strictly modify the way in which it 
functions, may be qualified as cosmetic products. The 
qualification of a product is to be decided by the 
national competent authorities, under the supervision of 
the courts, on a case-by-case basis, taking into account 
all the characteristics of the product. (European 
Commission, 2019a).
Finally, Directive 2014/40/EU on tobacco and related 
products (TPD) defines ‘herbal products for smoking’ as ‘a 
product based on plants, herbs or fruits which contains no 
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tobacco and that can be consumed via a combustion 
process’. The Directive in itself does not exclude the 
possibility that cannabis or related products may be 
included in herbal products for smoking. On the contrary, if 
these can be used for smoking, they need to comply with 
the provisions of the TPD. The TPD in itself does not lay out 
provisions on whether a product or its ingredients are legal 
or not, but intends to regulate products which can be 
legally placed on the market.
These products are specifically regulated by Articles 21 
and 22 of the TPD with specific provisions for product 
labelling and ingredients reporting. Prior to placing a new 
product on the market, manufacturers and importers need 
to submit to the national competent authorities a list of 
ingredients and respective quantities by brand name and 
type. Herbal products for smoking which contain or may be 
otherwise associated with cannabis were reported in more 
than 20 Member States to date with a notable increase in 
the number of products reported in the last two years 
(2019 and 2020). 
I Recent regulatory responses to the rise   in low-THC products
As policymakers in different countries around Europe have 
noticed the sale of low-THC products gaining increasing 
visibility, so the regulatory environment has started to 
change to both acknowledge and in some cases restrict 
their availability. At the EU level, there have also been some 
developments in this area.
In January 2019 the EU Novel food catalogue (see above) 
updated the entry relevant to low-THC cannabis, deleting 
the specific entry for CBD and inserting an entry for 
‘Cannabinoids’. This now states that:
[...] extracts of Cannabis sativa L. and derived products 
containing cannabinoids are considered novel foods, as 
a history of consumption has not been demonstrated. 
This applies to both the extracts themselves and any 
products to which they are added as an ingredient (such 
as hemp seed oil). This also applies to extracts of other 
plants containing cannabinoids. Synthetically obtained 
cannabinoids are considered as novel. (European 
Commission, 2019c).
In addition, in the area of cosmetics, several cannabis 
extracts or products, including CBD, are listed in 
Commission Decision (EU) 2019/701 as common 
ingredient names for use in the labelling of cosmetic 
products. Nevertheless, the European Commission has 
recently stated that cannabis extracts are banned in 
cosmetics, as they fall under the definition of ‘cannabis’, 
which is listed in Schedule 1 of the UN 1961 convention 
(European Parliament, 2019).
I Regulating THC levels at national level
The interpretations and applications of the legal 
frameworks in individual European countries differ. In 
some countries plant-derived low-THC or CBD-containing 
products are considered to be cannabis extracts, and 
therefore unlicensed sale is subject to criminal penalties, 
while in others they can be traded without a licence, as 
they are viewed as having insignificant psychoactive 
properties and therefore at low risk of misuse and unlikely 
to pose a threat to public health. Some countries state (by 
law or guideline) that a product containing less than 0.3 % 
or 0.2 % THC is not controlled under drug laws. Although 
quantitative limits of permitted THC exist, this is not 
always the only factor in national laws. Other 
circumstances may need to be considered when assessing 
legal status, such as the type of plant source, the reason 
the plant was grown, whether it was licensed, how the 
product was extracted and how the product was presented 
for sale. For example, quantitative limits may also come 
with stated conditions, such as ‘originating from an 
authorised variety of cannabis’, ‘if not viable for narcotic 
purposes’ or ‘if not misused’.
National variations in limits mean that products imported 
from a country with higher permitted THC levels, for 
example from Switzerland (where the national limit is 1 % 
THC), may breach another country’s national limits.
However, as well as variations in the levels set by countries, 
there are also differences in how levels of THC are set in 
Main EU legislation to be considered in the 
context of regulating low-THC cannabis products
   Medicinal products: Directive 2001/83/EC 
(medicinal products directive)
   Foods: Regulation (EC) No 178/2002
   Food supplements: Directive 2002/46/EC
   Novel foods: Regulation (EU) 2015/2283
   Cosmetics: Regulation (EC) No 1223/2009
   Tobacco products: Directive 2014/40/EU 
   Nutrition and health claims on foods: Regulation 
(EC) No 1924/2006
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different types of legislation, with laws applying to industrial 
uses, narcotics laws and assessments of food safety taking 
different approaches to establishing acceptable levels of 
THC (see box ‘Challenges in defining appropriate levels of 
THC in legislation’, on page 14). In 2018 Denmark 
changed its regulations and introduced a threshold limit 
that made it possible to produce and sell cannabis-based 
products containing up to 0.2 % THC without contravening 
national drug control legislation, while in 2019 Italy passed 
a decree defining the maximum levels of THC in food as 
2 milligrams per kilogram for hemp seeds and hemp flour 
and 5 milligrams per kilogram for hemp seed oil.
I Regulating CBD products
There are also national differences in the way CBD is 
regulated. If CBD is considered to have medicinal 
properties, it may be controlled and distributed under 
medicinal product regulations. Its access to the market will 
depend on the interest of companies to present 
applications for the marketing authorisation for a specific 
product. The EU framework for medicinal products does 
not allow for a broad recognition of a substance as a 
medicine. Each marketing authorisation request should be 
supported by data on safety, quality and efficacy, for a 
specific product. 
While permitted THC levels are commonly stated in 
legislation at national level, this does not appear to be the 
case for CBD levels. Furthermore, there is a range of 
extracts marketed as CBD with no clear definition of their 
exact content and a lack of evidence for their effects in 
humans. Generally, there seem to be few quantitative 
limits for CBD content but more focus on the conditions 
attached to its sale. In Romania, for example, any 
consumable product originating from cannabis is 
controlled under criminal law. In Denmark, CBD products 
(e.g. oils) are considered likely to have a pharmacological 
effect (based on product type, strength and dosage), and 
so they are regarded as medicinal products. In Finland, 
CBD has been clearly classed as a medicinal product, so 
unlicensed sale is not permitted.
In Austria the Federal Ministry of Social Affairs, Health, 
Care and Consumer Protection issued guidance in 
December 2018, stating that cannabis flowers should be 
sold as herbal smoking products to adults only with a 
health warning and that CBD-infused edibles would be 
classed as novel foods, and therefore it was illegal to sell 
them before a risk assessment had taken place. CBD 
extracts could not be marketed as dietary supplements, 
and the sale of CBD-containing cosmetics would no longer 
be permitted. In July 2019 Belgium issued a list of herbal 
products for smoking that could be marketed as long as 
the business operators are registered to pay excise tax – 
many product names are clearly cannabis related (e.g. 
‘kush’, ‘diesel’) (SPF Santé Publique, 2019a). An article 
accompanying this list highlighted that smoking products 
containing CBD must contain less than 0.2 % THC and 
must not be presented as having therapeutic properties, or 
as herbal teas or potpourri (SPF Santé Publique, 2019b). In 
some countries, the legality of marketing the product may 
depend on the source of the CBD, the format of the 
product or how the product is presented. It is not clear how 
online sales and marketing affects this.
Both the target group and the use to be made of the 
product can be a factor in determining appropriate intake 
levels and their regulation. In 2017 the European Industrial 
Hemp Association proposed that, for the average adult, 
products providing a daily oral intake of over 200 
milligrams of pure CBD should be regulated as medicinal 
products, those providing a daily oral intake of 20-160 
milligrams should be regulated as over-the-counter 
medicines or as food supplements, and amounts leading 
to a daily intake for adults of under 20 milligrams should be 
permitted in food products (EIHA, 2018).
In January 2019 there was also a proposal to change the 
UN drug control legislation relating to CBD. Following a 
critical review of cannabis and associated products by the 
World Health Organization (WHO) Expert Committee on 
Drug Dependence, a letter from the Director-General of 
the WHO to the UN Secretary-General, dated 24 January 
2019, put forward six recommendations, including that 
there should be a footnote to the entry for cannabis and 
cannabis resin in Schedule I of the 1961 convention that 
would read ‘Preparations containing predominantly 
cannabidiol and not more than 0.2 % of delta-9-THC are 
not under international control’.
In March 2020 the UN Commission on Narcotic Drugs 
decided to vote at its reconvened 63rd session on the six 
WHO recommendations on the international control of 
cannabis and cannabis-related substances. The UN 
Commission on Narcotic Drugs decided on 2 December 
2020 (by 27 votes to 25 and with one abstention) to delete 
cannabis and cannabis resin from Schedule IV of the 1961 
Convention. These substances remain in Schedule I of the 
1961 Convention and thus remain subject to all levels of 
control of the 1961 Convention. The Commission decided 
not to follow the other recommendations made by the WHO. 
In 2018 a business in France imported low-THC cannabis 
oil from Czechia and began to sell it to the public in 
e-cigarette cartridges, promoting its CBD content. The 
oil was made from the whole cannabis plant, which is 
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legal in Czechia but not in France, where the commercial 
use of hemp is restricted to fibre and seeds. The 
business owner was convicted, and appealed. The case 
was referred to the European Court of Justice (C-
663/18), which declared in November 2020 that while 
the CBD in the case was not a drug within the meaning 
of the 1961 Convention, the fundamental principle of 
free movement of goods between Member States could 
still be limited on grounds of the protection of the health 
and life of humans. However, such a limit should not go 
beyond what is necessary in order to achieve its 
objective, and should be applied in a consistent and 
systematic manner. The Court stated that, while the 
evidence of CBD posing a risk to health was still limited 
but may justify precautionary restrictive measures, it was 
inconsistent to apply the marketing ban only to organic, 
and not synthetic, CBD.
The court’s statement that CBD was not a drug within the 
meaning of the 1961 Convention has implications for 
interpretations of the EU laws discussed above: these may 
be addressed in the near future.
The legislative framework originally intended for the 
hemp industry, which is based on the percentage of 
THC in hemp, is not appropriate for the many variants 
of cannabis product that have recently appeared on the 
market and should not be used as surrogate safety limits 
for human consumption without further checks. 
The percentage of THC can be measured and referred to 
at a variety of levels.
  The level of THC that a certain variety of cannabis 
plant will usually produce. This serves to distinguish 
between legal hemp and illegal cannabis plantations.
  The levels found in the different parts of the plant. 
Levels are lowest in the roots, stalks and seeds, 
higher in the leaves and highest in flowers and resin. 
This serves to distinguish what parts of the plant may 
be used for industrial purposes without extensive 
testing, or what might be of value to divert to illegally 
extracting THC.
  The level found in the extracts. This may be used to 
indicate whether an extract (usually oil) has 
intoxicating properties or not.
  The level found in the final consumable product, for 
example an edible product. 
The input (ingredient) is easier for the producer to 
control, but the output (product) is more relevant when 
considering the effect on the consumer. Nevertheless, it 
is possible to grow low-THC hemp and from it produce 
a high-THC extract, highlighting the importance of 
considering the final product and not just the input 
material. 
Currently there may be inconsistency between laws 
applying to industrial uses and narcotics laws with 
respect to whether percentage or weight is used to 
determine the amount of THC in a product. It may 
be possible for a product (e.g. oil) containing a low 
percentage of THC that is within the permitted industrial 
levels to exceed the total weight of THC permitted under 
narcotics laws. For example, 500 millilitres of ‘CBD oil’ 
containing 0.2 % THC will contain approximately 1 gram 
of THC, a threshold for narcotics possession or sale 
offences in some countries.
Canada and the US state of Colorado have set limits 
of 10 milligrams of THC in one ‘unit’ of a (recreational) 
edible product for intoxication, such as one (square of) a 
chocolate bar. In Canada, 10 milligrams of THC is sold in 
a 32-gram bar of chocolate, resulting in an intoxicating 
dose being sold at a concentration of barely 0.03 %.
In the case of food safety levels, the concept of a 
maximum safe daily dose is used. The European Food 
Safety Agency (EFSA) uses the acute reference dose of 
a substance when carrying out risk assessments of food 
products and contaminants; the acute reference dose 
is the maximum dose per kilogram of body weight per 
day that is deemed safe. The EFSA reference dose for 
THC of 1 microgram per kilogram was calculated using 
an uncertainty factor of 30. The European Industrial 
Hemp Association considers that, in comparison with the 
uncertainty factor of 3 for opium alkaloids in foods such 
as poppy seeds, this produces a limit for THC in food 
that is excessively cautious (EIHA, 2017). In Austria and 
Switzerland, the uncertainty factor has been reduced to 
10. In New Zealand the maximum safe daily THC intake is 
7 micrograms per kilogram body weight with no apparent 
problems reported, and Canada’s industrial hemp 
regulations of 2019 exclude products from the Cannabis 
Act if they contain no more than 10 micrograms of THC 
per gram of product. 
Challenges in defining appropriate levels of THC in legislation 
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I Quality control and law enforcement
A number of participants in this study, coming from a 
criminal justice background, highlighted the fact that the 
tasks of law enforcement and customs bodies have 
become more complicated now that low-THC cannabis 
products are appearing on open sale. One issue is lack of 
clarity over which regulatory framework should be applied 
in any particular situation. Customs officers, for example, 
may be seizing products that claim to have low THC levels 
and would thus fall outside drug control laws in some 
countries, but the products may in fact have illegal levels 
of THC. Currently the only way to determine whether a 
product is legal or not is to test its content, a process that 
can be both expensive and time consuming. The sale of 
low-THC cannabis herb and resin products therefore poses 
a new challenge for law enforcement, as distinguishing 
between low- and high-THC cannabis on the street, in 
shops or at the border is not simple, and it is impractical 
and costly to test all products. In Austria, Italy, and 
Switzerland, the police now have a rapid reagent test for 
use on the street; some portable tests can analyse 
whether a product contains THC or not and others analyse 
the amount of THC. Not all law enforcement agencies 
across Europe have these instruments available, however. 
It is also important that, even when tested in a laboratory, it 
can be difficult to achieve consistent results from the same 
product (Giese et al., 2015).
I Looking to the future: what traction do   low-THC products have?
The argument can be made that the change in the law in 
Switzerland helped to provide the foundation for the 
introduction of low-THC cannabis products on to the 
European market and that the perceived grey area around 
these products’ legality and promotion has helped this 
market to expand rapidly, to the extent that the open sale 
of these products is now common across Europe. In 
contrast, it can be argued that producers wanting to 
manufacture products containing low amounts of extracts 
from the cannabis plant or products containing synthetic 
versions of CBD, to meet consumer demand, are 
hampered by the lack of a clear regulatory framework in 
this area. These developments have not occurred within a 
vacuum, however. The wider political and cultural 
environment, including recent legalisations in Canada and 
some US states, may have contributed to the market’s 
growth and arguably potentially added to the normalisation 
of sales of products containing cannabis extracts.
Understanding developments in this dynamic area is also 
handicapped by a lack of information. There is currently 
very limited information on the range of products available 
in Europe and who is using them, beyond the studies in 
Austria and Switzerland highlighted in this report. There 
is also no information available on the extent of use of 
these products. Given that many of these substances 
are traded across borders, it may be helpful to undertake 
cross-national studies and develop standard monitoring 
tools to collect information on the products available 
and the people using them to improve understanding of 
developments in this area.
From the information available it appears that for many 
users of CBD-containing products the motivation for use is 
linked to anticipated health and well-being benefits. 
However, while some cannabis-based products are 
currently being advertised as highly beneficial for certain 
medical conditions, such as insomnia, loss of appetite, 
depression and digestive problems, the evidence for the 
effects of CBD and THC on the body and in relation to 
most of these conditions is limited. Where self-reported 
findings or results from trials exist, because of the 
combinations of cannabinoids and compounds in cannabis 
and the difficulty in measuring dosage, claiming any 
consistent health benefit of openly sold CBD products 
is difficult.
A greater understanding of appropriate safety limits for 
THC and CBD is required to enable a more thorough 
assessment of the potential harms and benefits of 
low-THC cannabis products. When establishing such 
limits, different forms of the product will need to be taken 
into account, as the bioavailability of THC will differ; 
transdermal creams and ingested foods with similar THC 
contents will have different effects on the brain. It is also 
not yet known whether there may be other long-term risks 
associated with the use of such products. This is a rapidly 
changing market and developments are likely, which may 
change the risk/benefit profile over time. For example, 
some manufacturers are finding ways to make THC water 
soluble, which increases its bioavailability, so there is the 
potential for drinks containing THC to be more potent. This 
highlights a need to support more research into the 
benefits and harms to health as well as establishing a 
system for reporting adverse effects from consuming 
these products.
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There appears to have been something of a ‘gold rush’ 
atmosphere among entrepreneurs selling low-THC 
products, with shops rapidly opening and closing, and the 
situation in flux. Keeping abreast of regulatory changes will 
be a challenge for small businesses, and increasing 
regulation is likely to favour bigger companies. Some 
businesses have reported problems when dealing with 
global payment providers such as Visa, Mastercard and 
PayPal; they are based in the United States, which at the 
federal level does not permit sales of cannabis products. 
The internet also appears to be playing a crucial role in the 
expansion of this phenomenon, and several mainstream 
marketplace platforms and social media applications offer 
these types of products. Regulation in the virtual 
environment can be challenging for many products, and 
these challenges are likely to be particularly pronounced in 
this area.
Another issue highlighted in this report concerns the 
labelling and marketing of low-THC products in ways that 
may make it difficult to identify the relevant legal 
framework that would apply to their sale (e.g. narcotics 
laws, smoking control, food quality control). This is not an 
entirely new phenomenon, as similar regulatory issues 
arose when new psychoactive substances started 
appearing for sale on the European drug market. One 
example is the use of disclaimers, such as ‘not for human 
consumption’, that attempt to shift responsibility for 
consumption to the user. Consumer protection requires the 
seller to ensure that products are clearly labelled, which 
would mean that products could be classified and covered 
by the relevant national legislation on safety, advertising, 
etc. Industry bodies have themselves called for greater 
clarity around the regulations that apply, and this may be 
an opportunity for policymakers and trade bodies to work 
together to design regulatory standards that may protect 
consumers from the most serious threats presented by the 
current unregulated industry. In labelling products, 
policymakers will need to address not only safety limits but 
also the confusing message given to the consumer by 
using different measurements of THC and CBD content 
and whether the percentage of THC, maximum dose per 
day or ratio of THC to CBD should be used.
The increased availability of low-THC cannabis products on 
the market also gives rise to broader questions about the 
possible impact on the public’s attitude to cannabis use. 
One line of argument suggests that the increase in 
accessibility can be considered a form of ‘soft legalisation’; 
another proposes that the phenomenon represents an 
increasing public nuisance; a third asks if the restrictions 
on the substance are disproportionate, as it does not 
appear to threaten public health. Public opinion aside, it is 
likely that European countries will experience a period 
involving some balancing of low-THC product supply and 
demand on the one hand and challenges for regulators on 
the other, including managing the issues associated with 
varying product quality. In terms of the products sold, there 
are some indications that one of the products with the 
greatest potential for lasting demand is CBD oil. It remains 
to be seen if the demand for cosmetic products containing 
cannabis extracts grows in the future. There is also a 
debate on the extent to which low-THC cannabis products 
are likely to be attractive to consumers seeking a legal 
substitute for illicit cannabis, given that these products do 
not produce the intoxicating effects associated with illicit 
cannabis. There are therefore many unknowns in this area 
that complicate discussions on what should constitute a 
reasonable and proportionate policy response. One thing 
is clear, however: future consideration of what constitutes 
an appropriate response to developments in this area will 
benefit from a better understanding of this diverse and 
dynamic phenomenon, and public health and consumer 
protection concerns will require a greater knowledge base 
for both low-THC and CBD-containing products and their 
actual contents, forms and short- and long-term effects.
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information centres. You can find the address of the centre nearest you 
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EU law and related documents
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About this publication
The open sale of cannabis products in Europe has 
raised concerns among policymakers, both with regard 
to the legal status of these products and their potential 
for harm. The products are marketed for their low THC 
(tetrahydrocannabinol) content, which sellers claim 
exempt them from control by drug laws, or as sources 
of CBD (cannabidiol). This publication presents an 
initial overview of the situation, covering the types of 
low-THC products available, user profiles, associated 
harms and regulatory responses in Europe. Low-THC 
products that take forms similar to illicit cannabis 
products, such as smoking mixtures, oils and edibles 
are a primary focus of this study. The report highlights 
the challenges facing both policymakers and those 
wishing to supply low-THC products regarding 
establishing the legal status of the products and which 
regulatory frameworks apply to their sale.
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The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level. 
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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